NASDAQ:PLYX Polaryx Therapeutics (PLYX) Stock Price, News & Analysis $1.77 -0.11 (-5.85%) Closing price 11/13/2026 03:56 PM EasternExtended Trading$1.84 +0.07 (+3.95%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsSEC Filings About Polaryx Therapeutics Stock (NASDAQ:PLYX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Polaryx Therapeutics alerts:Sign Up Key Stats Today's Range$1.77▼$1.8850-Day Range$1.73▼$2.1552-Week Range$1.69▼$48.91Volume10,404 shsAverage Volume22,442 shsMarket Capitalization$88.23 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingModerate Buy Company Overview Polaryx Therapeutics is a biotechnology company focused on developing treatments for rare genetic diseases. Its research and development activities target conditions with significant unmet medical needs, including disorders that affect the nervous system and metabolism. The company’s work centers on advancing drug candidates for these conditions. Publicly available information about its specific products, commercial operations, geographic reach and leadership is limited.AI Generated. May Contain Errors. Read More Polaryx Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScorePLYX MarketRank™: 1.874835828735 of 5 starsPolaryx Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 710th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingPolaryx Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPolaryx Therapeutics has a consensus price target of $7.67, representing about 333.1% upside from its current price of $1.77.Amount of Analyst CoveragePolaryx Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Polaryx Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Polaryx Therapeutics are expected to decrease in the coming year, from ($0.20) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Polaryx Therapeutics is -22.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Polaryx Therapeutics is -22.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPolaryx Therapeutics has a P/B Ratio of 17.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.51% of the float of Polaryx Therapeutics has been sold short.Short Interest Ratio / Days to CoverPolaryx Therapeutics has a short interest ratio ("days to cover") of 6.48.Change versus previous monthShort interest in Polaryx Therapeutics has recently increased by 16.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPolaryx Therapeutics does not currently pay a dividend.Dividend GrowthPolaryx Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.58 News SentimentPolaryx Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Polaryx Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Polaryx Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders45.82% of the stock of Polaryx Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPolaryx Therapeutics has minimal institutional ownership at this time.Read more about Polaryx Therapeutics' insider trading history. Receive PLYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Polaryx Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLYX Stock News HeadlinesHC Wainwright Issues Optimistic Forecast for PLYX EarningsNovember 14 at 2:05 AM | americanbankingnews.comPolaryx Activates First Site For Phase 2 SOTERIA Trial Of PLX-200November 9, 2026 | rttnews.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 15 at 1:00 AM | Behind the Markets (Ad)Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200November 9, 2026 | globenewswire.comPolaryx Therapeutics Appoints New Chief Medical OfficerSeptember 1, 2026 | tipranks.comPolaryx Appoints Charlton As CMO; PLX-200 Set For Phase 2 In Q4 '26September 1, 2026 | rttnews.comPolaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical OfficerSeptember 1, 2026 | globenewswire.comPolaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket TrialAugust 25, 2026 | globenewswire.comSee More Headlines PLYX Stock Analysis - Frequently Asked Questions How have PLYX shares performed this year? Polaryx Therapeutics' stock was trading at $2.61 on February 20, 2026. Since then, PLYX shares have decreased by 32.2% and is now trading at $1.77. How were Polaryx Therapeutics' earnings last quarter? Polaryx Therapeutics, Inc. (NASDAQ:PLYX) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. When did Polaryx Therapeutics IPO? Polaryx Therapeutics (PLYX) raised $0 in an initial public offering (IPO) on the week of February 2nd 2026. The company issued 47,343,297 shares at a price of $0.00 per share. How do I buy shares of Polaryx Therapeutics? Shares of PLYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PLYX CIK2075320 Webpolaryx.com Phone(201) 940-7236FaxN/AEmployees11Year Founded2014Price Target and Rating Average Price Target for Polaryx Therapeutics$7.67 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+333.1%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.53 Quick Ratio13.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book17.70Miscellaneous Outstanding Shares49,850,000Free Float27,007,000Market Cap$88.23 million OptionableN/A BetaN/A Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:PLYX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polaryx Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polaryx Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.